Recent News

• 10.01.2025 - CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
• 10.01.2025 - CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
• 09.10.2025 - CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
• 09.10.2025 - CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
• 08.14.2025 - CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights

Recent Filings

• 09.17.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.16.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.15.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.11.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 09.11.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership